Stockscreener 앱 받기
3.01
2.59%
-0.08
시간 외 거래:
3.04
0.03
+1.00%
전일 마감가:
$3.09
열려 있는:
$3.12
하루 거래량:
4.31M
Relative Volume:
0.93
시가총액:
$798.09M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-10.75
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
-3.53%
1개월 성능:
-15.45%
6개월 성능:
+64.48%
1년 성능:
+98.03%
1일 변동 폭
$2.98
$3.15
1주일 범위
$2.98
$3.32
52주 변동 폭
$1.24
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.01 | 819.30M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
155.37 | 68.60B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.86 | 46.99B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.71 | 43.17B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.05 | 20.82B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
305.35 | 13.98B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
What’s the recovery path for long term holders of Akebia Therapeutics Inc.Quarterly Portfolio Report & AI Forecast for Swing Trade Picks - Newser
Is Akebia Therapeutics Inc. stock reversal real or fakeTreasury Yields & Weekly Chart Analysis and Trade Guides - Newser
Akebia Therapeutics Inc. stock trend forecastPortfolio Value Summary & AI Enhanced Market Trend Forecasts - Newser
What candlestick patterns are forming on Akebia Therapeutics Inc.Earnings Growth Summary & Free Community Supported Trade Ideas - Newser
Analyzing drawdowns of Akebia Therapeutics Inc. with statistical toolsCEO Change & Weekly Momentum Picks - Newser
What Fibonacci levels say about Akebia Therapeutics Inc. reboundGlobal Markets & Expert Approved Trade Ideas - Newser
How moving averages guide Akebia Therapeutics Inc. tradingJuly 2025 Update & Short-Term High Return Ideas - Newser
Tools to monitor Akebia Therapeutics Inc. recovery probabilityJuly 2025 Outlook & Short-Term High Return Ideas - Newser
Is Akebia Therapeutics Inc. showing signs of accumulation2025 Technical Patterns & Safe Entry Momentum Stock Tips - Newser
How to manage a losing position in Akebia Therapeutics Inc.Rate Hike & Weekly Watchlist of Top Performers - Newser
Is Akebia Therapeutics Inc. reversing from oversold territoryJuly 2025 Momentum & Short-Term Swing Trade Alerts - Newser
Why Akebia Therapeutics Inc. stock attracts strong analyst attention2025 Fundamental Recap & Risk Controlled Stock Alerts - Newser
Detecting price anomalies in Akebia Therapeutics Inc. with AIPortfolio Gains Report & Daily Technical Forecast Reports - Newser
Published on: 2025-08-26 12:34:55 - Newser
Understanding Akebia Therapeutics Inc.’s price movementCPI Data & Stock Market Timing Techniques - Newser
Visual trend scoring systems applied to Akebia Therapeutics Inc.Quarterly Investment Review & Fast Moving Trade Plans - Newser
What’s next for Akebia Therapeutics Inc. stock price2025 Volatility Report & Community Shared Stock Ideas - Newser
Regression analysis insights on Akebia Therapeutics Inc. performance2025 Year in Review & Stock Portfolio Risk Control - Newser
Published on: 2025-08-25 03:01:58 - Newser
News impact scoring models applied to Akebia Therapeutics Inc.2025 Price Action Summary & Community Driven Trade Alerts - Newser
How to interpret RSI for Akebia Therapeutics Inc. stockJuly 2025 Breakouts & Long Hold Capital Preservation Plans - Newser
How to use a screener to detect Akebia Therapeutics Inc. breakoutsInsider Buying & Free Verified High Yield Trade Plans - Newser
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo across All IRC Dialysis Clinics - MarketScreener
Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth - MSN
Is Akebia Therapeutics Inc. stock heavily shortedJuly 2025 Closing Moves & Safe Capital Growth Plans - theviewers.co.kr
Is Akebia Therapeutics Inc. in Accumulation Phase NowTreasury Yields & Free Reliable Trade Execution Plans - 더경남뉴스
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® Across All IRC Dialysis Clinics - MarketScreener
Akebia’s Vafseo now available across Innovative Renal Care clinics - Investing.com
Akebia Therapeutics and Innovative Renal Care Announce - GlobeNewswire
55,000 Patients Now Have Access: Akebia's Vafseo Anemia Drug Rolls Out Nationwide at IRC Clinics - Stock Titan
When is the best time to buy Akebia Therapeutics Inc. stockJuly 2025 Breakouts & Weekly High Return Opportunities - Newser
Using Ichimoku Cloud for Akebia Therapeutics Inc. technicalsPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Detecting support and resistance levels for Akebia Therapeutics Inc.July 2025 Momentum & Accurate Trade Setup Notifications - Newser
Akebia Therapeutics Inc. Ranks High in Smart Money TrackerPortfolio Return Report & Breakout Confirmation Trade Signals - 선데이타임즈
How to monitor Akebia Therapeutics Inc. with trend dashboardsTrade Signal Summary & Smart Swing Trading Alerts - Newser
Momentum divergence signals in Akebia Therapeutics Inc. chartTrade Performance Summary & Free Real-Time Market Sentiment Alerts - Newser
How Interest Rate Changes Impact Akebia Therapeutics Inc. Stock Performance2025 Support & Resistance & Weekly Momentum Picks - Newser
Akebia Therapeutics Inc. stock trend outlook and recovery pathQuarterly Portfolio Review & Entry Point Confirmation Signals - Newser
Using Bollinger Bands to evaluate Akebia Therapeutics Inc.2025 Key Lessons & Weekly Watchlist for Hot Stocks - Newser
Published on: 2025-08-16 04:38:08 - Newser
Price momentum metrics for Akebia Therapeutics Inc. explained2025 Earnings Surprises & Trade Opportunity Analysis Reports - Newser
What makes Akebia Therapeutics Inc. stock price move sharply2025 Key Lessons & Safe Entry Point Alerts - sundaytimes.kr
Akebia Therapeutics Reports Record Revenue and Strategic Growth - The Globe and Mail
Akebia at Canaccord Conference: Strategic Growth in Anemia Treatment By Investing.com - Investing.com Canada
Bollinger Bands Show Potential Breakout in Akebia Therapeutics Inc.July 2025 Fed Impact & Entry Point Confirmation Alerts - beatles.ru
Does Akebia Therapeutics Inc. have declining or rising EPSVerified 200% Stock Tips - thegnnews.com
Is AKBA anticipated to rise today? - AInvest
The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - ca.finance.yahoo.com
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
1.25%
자본화:
|
볼륨(24시간):